BPC-157: A Gastric Peptide That Accelerates Wound Healing Across Nearly Every Tissue Type
BPC-157, a stable peptide derived from gastric juice, promotes wound healing in skin, gut, tendon, bone, nerve, and blood vessels through vessel regulation, clot management, and gene activation — with no reported toxicity in animal studies.
Quick Facts
What This Study Found
BPC-157 promotes wound healing across virtually all tissue types through vessel regulation, clot management, and rapid gene expression activation, effective at both µg and ng doses via oral or injectable routes.
Key Numbers
No reported toxicity; LD1 not achieved; effective at µg and ng doses; oral and injectable routes equipotent; heals skin, gut, tendon, ligament, muscle, bone, nerve, spinal cord, cornea, blood vessels
How They Did This
Comprehensive review of animal studies on BPC-157 wound healing, covering skin wounds, fistulas, burns, diabetic ulcers, and multiple internal tissue types.
Why This Research Matters
A single peptide that promotes healing across so many tissue types through common mechanisms could have wide therapeutic applications, from surgical recovery to chronic wound management.
The Bigger Picture
BPC-157 occupies a unique position in peptide research — it has one of the most extensive preclinical evidence bases of any experimental peptide, spanning dozens of tissue types and injury models. However, nearly all research comes from a single laboratory group in Croatia, and the lack of independent replication and large human trials has limited mainstream acceptance. The peptide's multi-tissue healing capability through common mechanisms (vascular regulation, gene activation) makes it a fascinating case study in regenerative peptide biology.
What This Study Doesn't Tell Us
Based almost entirely on animal studies. Clinical trial data is limited to ulcerative colitis and multiple sclerosis. No large randomized controlled trials for wound healing in humans. Many studies come from the same research group.
Questions This Raises
- ?Why has BPC-157 not progressed to large-scale human clinical trials for wound healing despite decades of animal evidence?
- ?Would independent laboratory replication of these results strengthen the case for clinical development?
- ?Could BPC-157 be combined with standard wound care protocols to accelerate healing in diabetic ulcers or surgical recovery?
Trust & Context
- Key Stat:
- No toxicity (LD1 not achieved) In extensive animal testing, BPC-157 showed no reportable toxicity even at the highest doses tested — the dose that would kill 1% of animals (LD1) was never reached.
- Evidence Grade:
- This is a comprehensive review of primarily animal (rat) studies from a prolific but concentrated group of researchers. While BPC-157 has been used in human trials for ulcerative colitis and multiple sclerosis, no large randomized controlled trials for wound healing in humans have been conducted. The evidence is extensive but predominantly preclinical.
- Study Age:
- Published in 2021, this review summarizes decades of BPC-157 research. The peptide remains one of the most discussed experimental peptides in regenerative medicine, though clinical translation has been slow.
- Original Title:
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
- Published In:
- Frontiers in pharmacology, 12, 627533 (2021)
- Authors:
- Seiwerth, Sven(44), Milavic, Marija(3), Vukojevic, Jaksa(2), Gojkovic, Slaven, Krezic, Ivan, Vuletic, Lovorka Batelja, Pavlov, Katarina Horvat, Petrovic, Andrea, Sikiric, Suncana, Vranes, Hrvoje, Prtoric, Andreja, Zizek, Helena, Durasin, Tajana, Dobric, Ivan, Staresinic, Mario, Strbe, Sanja, Knezevic, Mario, Sola, Marija, Kokot, Antonio, Sever, Marko, Lovric, Eva, Skrtic, Anita, Blagaic, Alenka Boban, Sikiric, Predrag
- Database ID:
- RPEP-05748
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is BPC-157 and where does it come from?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein found naturally in human gastric (stomach) juice. It is classified as 'stable' because unlike many peptides, it doesn't break down quickly in stomach acid, which is why it can be taken orally.
Is BPC-157 approved for medical use?
No. Despite extensive animal research showing healing benefits across many tissue types, BPC-157 is not approved by the FDA or other major regulatory agencies for any medical condition. It has been tested in small human trials for ulcerative colitis and multiple sclerosis, but large-scale clinical trials for wound healing have not been conducted.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05748APA
Seiwerth, Sven; Milavic, Marija; Vukojevic, Jaksa; Gojkovic, Slaven; Krezic, Ivan; Vuletic, Lovorka Batelja; Pavlov, Katarina Horvat; Petrovic, Andrea; Sikiric, Suncana; Vranes, Hrvoje; Prtoric, Andreja; Zizek, Helena; Durasin, Tajana; Dobric, Ivan; Staresinic, Mario; Strbe, Sanja; Knezevic, Mario; Sola, Marija; Kokot, Antonio; Sever, Marko; Lovric, Eva; Skrtic, Anita; Blagaic, Alenka Boban; Sikiric, Predrag. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.. Frontiers in pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533
MLA
Seiwerth, Sven, et al. "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.." Frontiers in pharmacology, 2021. https://doi.org/10.3389/fphar.2021.627533
RethinkPeptides
RethinkPeptides Research Database. "Stable Gastric Pentadecapeptide BPC 157 and Wound Healing." RPEP-05748. Retrieved from https://rethinkpeptides.com/research/seiwerth-2021-stable-gastric-pentadecapeptide-bpc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.